diagnost tool
biomed devic servic
diagnost tool
 key updat precis
medicin week rais pt
follow flurri news event week highlight key updat provid
compani coverag view amend suppli agreement
final prospera lcd kidney transplant reject test de-risk
event compani cogs/test target transplant rev expect
remain appropri manag nudg pt use
rais multipl unchang revenu y/i
settl nipt patent disput amend suppli agreement
bode well cogs/test improv begin octob
releas yesterday announc reach settlement
regard nipt patent litig begin octob fee payabl
clinic nipt test perform use reagent
reduc reduct increas volum bound
exclus use ilmn sequenc instrument reagent conduct
sequenc avail discount may affect reduc volum
sequenc platform offer credit purchas
instrument use oncolog organ transplant monitor product develop
contribut product off-set portion ntra new oncolog product
develop view announc big win off-set
estim annual price increas ilmn sequenc product remind
deliv cogs/test long-term goal
believ today announc may serv catalyst drive ntra long-term
cogs/test target somewher closer rang potenti
compani advanc core nipt busi toward cash flow break-even
noridian final lcd prospera test monday announc
california medicar administr contractor noridian final lcd
prospera kidney transplant reject begin bill medicar
understand noridian develop gener polici dd-cfdna test
demonstr sensit improv simoa ahead
goal driven magnet bead load improv optic algorithm
improv improv signal-to-nois ratio simoa protein
detect technolog power hd-x sr-x analyz demonstr
sensit improv already-market-lead detect capabl
sensit improv expect enabl enhanc detect neurolog
biomark plasma serum allow research better see blood
see cerebrospin fluid csf expect sensit improv allow
detect inflammatori cytokin blood healthi diseas patient
detect protein import earli accur detect infecti
agent begun offer research access improv sensit test
acceler servic lab view updat posit may attract
new wave research gear toward neurolog biomark previous capabl
detect blood draw
provid insight serolog assay monday announc
research develop serolog test use simoa detect measur igg
igm iga antibodi four immunogen viral protein result studi
demonstr simoa assay detect seroconvers soon one day
symptom onset use less microlit plasma sampl size patient
demonstr sensit specif first week
infect sensit specif thereaft process
convert test commerci viabl solut launch soon
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
diagnost tool
genom england announc project sequenc
genom morn genom england announc plan sequenc
whole genom support research
sequenc cambridg lab intend offer sequenc servic
discount normal price view announc sign interest
popul genom popgen project like elev back side
omead ostadan exit join proteom compani seer omead ostadan
senior vice presid chief product market offic leav
compani earli june becom presid privat held seer
explor role proteom pre-symptomat detect cancer
neurolog diseas applic see similar differ
seer latter continu execut runway neurolog
branch oncolog infecti diseas applic seer
appear priorit oncolog earli diseas detect
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author
analyst knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ
person canaccord genuiti llc therefor may subject finra rule nyse rule restrict
commun subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
pt use multipl ep estim
pt use multipl revenu
pt use multipl rev discount back year discount rate
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat
excess peer group risk associ demand pace novaseq placement hiseq unit
decommiss competit noise/tract though believ meaning competit risk well bay nih/
govern budgets/spend particularli foreign govern like japan genom research center regulatori
risk fda addit risk factor less concern includ typic medic technolog risk price instrument
consum risk associ move test clinic increas compani focu bioinformat
long-term also highlight spend scale helix
panorama asp compress erod margin gross margin drop sequenti
expect margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress
drive busi profit account though busi may suffer increas test volum outpac
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership
may particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat
certain ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin
deem highest-risk devic follow lower risk devic believ panorama would treat moderate-risk
high-risk among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect
requir remov product market regul fda ltd remain subject uncertainti
controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori
clearanc market constel softwar diagnost purpos abl secur fda clearanc
diagnost tool
compli on-going fda regulatori requir would unabl commerci constel compani cloud-
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
futur advers impact busi
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung
ovarian cancer collect dozen collabor includ vanderbilt stanford columbia cancer research
uk other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base
revenu data addit player includ foundat medicin roch grail person genom diagnost genom
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test natera
test provid dna test servic like conduct use panorama expect conduct oncolog may
rais ethic legal social issu regard privaci appropri use result inform government author
could social purpos limit regul use genom inform genom test prohibit test genet
predisposit certain condit particularli known cure similarli concern may lead patient
refus use genet test even permiss ethic social concern may also complic abil protect patent
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest
payor term dollar
small-cap compani risk share price volatil small-cap compani low trade liquid thu may
difficult investor sell share quickli favor price rel competitor public market found
lack establish oper histori may make difficult effect compet larger competitor small-
cap compani gener less avail inform public domain make hard fulli evalu busi
access capit balanc sheet small public compani may less access capit make harder
bridg gap cash flow fuel growth opportun undertak larg capit expenditur hold cash
balanc sheet burn cash capit expenditur requir includ sale market expans research
develop exist product improv new product develop launch regulatori clearanc facil
headcount expans oper financi inform system cost unabl secur addit
fund need may delay reduc scope elimin one research develop program
sale market initi
time profit accumul deficit expect loss continu least
next month profit reli continu top-lin growth success instrument assay
launch expans commerci organ market penetr util uptak delay instrument test
launch regulatori reimburs decis health custom purchas environ may extend quanterix
goal profit face challeng competitor face life scienc research market includ rapid
standard intellectu properti disput price competit aggress market practic need invest
infrastructur advanc increas demand instrument test failur accur forecast demand would
neg impact busi abil attain profit
commerci risk market accept market accept depend compani abil improv exist product
introduc new product success prove offer novel attract altern compet
technolog face risk relat custom acquisit technolog valid sale cycl instrument/test accuraci
reliabl prove econom benefit adopt technolog success depend compani abil cater
divers custom base includ academ government research institut well biopharmaceut
contract research compani face risk relat talent acquisit expans direct sale forc abil
identifi secur desir third-parti sale distribut partner custom demand depend level research
develop spend academ government research institut biopharma compani
exclus strateg collabor licens arrang look establish strateg collabor
licens agreement third parti develop product base simoa technolog certain vitro diagnost
ivd purpos counterparti partner priorit collabor abil gener revenu
agreement may limit given exclus natur certain collabor may abl collabor
other area exclus licens effect
relianc singl contract manufactur reli singl contract manufactur locat germani
manufactur suppli simoa analyz instrument reli singl contract manufactur locat california
diagnost tool
manufactur suppli sr-x instrument manufactur disrupt priorit project ahead delay
suppli would neg affect oper result chang manufactur would result addit cost delay
manag execut human capital- attract retain talent success includ research
develop program commerci execut larg depend continu abil identifi hire develop motiv
retain highli skill personnel area organ given complex technic natur life scienc research
market failur attract recruit retain motiv qualifi personnel may pose risk
competit life scienc research diagnost compet directli compani servic
life scienc research diagnost market includ luminex corpor mesoscal diagnost singulex gyro
corpor inc upon expans health screen market siemen abbott roch ortho
clinic diagnost thermo fisher scientif face competitor hold greater brand recognit greater financi
human resourc broader product line larger sale forc distributor network larger ip portfolio establish custom
base larger scale manufactur capabl
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
relev issuer
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
current past month client canaccord genuiti affili compani
period canaccord genuiti affili compani provid invest bank servic
past month canaccord genuiti affili compani receiv compens invest bank servic
past month canaccord genuiti affili compani lead manag co-lead manag co-
manag public offer secur publicli disclos offer secur
relat deriv
canaccord genuiti one affili compani market maker liquid provid secur
relat deriv
canaccord genuiti one affili compani intend seek expect receiv compens invest
bank servic next three month
analyst visit materi oper payment receiv relat travel cost
rate histori
diagnost tool
rate histori
rate histori
line articl mifid ii deleg regul disclos price perform preced five year
whole period financi instrument offer invest servic provid less five year pleas
diagnost tool
note price histori refer actual past perform past perform reliabl indic futur price and/or
